Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by PsychoGenics Inc.

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Inc. Awarded $3 Million SBIR Grant to Employ Its AI-Enabled Platforms to Find Treatments for Rare Disorders
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Launches an Updated Corporate Identity and Brand
From PsychoGenics Inc.
Via Business Wire
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
From PsychoGenics Inc.
Via Business Wire
Tickers KRTX
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities
From PsychoGenics Inc.
Via Business Wire
PsychoGenics’ High Data Security Standards Are Certified by The NIH
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development
From PsychoGenics Inc.
Via Business Wire
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
From PsychoGenics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.